VolitionRx assumed with a Buy at EF Hutton

EF Hutton assumed coverage of VolitionRx with a Buy rating and $5 price target. Volition is a multi-national epigenetics company that has patented technologies that use chromosomal structures, such as nucleosomes and transcription factors, as biomarkers in cancer and other diseases and is trying to “imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests,” the analyst tells investors. Over the coming year, the company hopes to see its veterinary product build, out-license its oncology/immunology tests in man, and see those move to commercialization, the analyst noted.